<DOC>
	<DOCNO>NCT02685332</DOCNO>
	<brief_summary>Radiation , Stereotactic Body Radiation Therapy .</brief_summary>
	<brief_title>Phase I Dose Escalation Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA</brief_title>
	<detailed_description>In protocol , plan use uniqueness Cyberknife system deliver adjuvant single fraction radiation dose . We anticipate radiation deliver system reduce toxicity improve cosmesis . Extrapolating intra-operative body work , Phase I study attempt achieve non-invasive low toxicity profile maintain good excellent cosmesis . In effort , Cyberknife system use achieve high conformality dose gradient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Ductal carcinoma situ ( DCIS ) invasive epithelial ( ductal , medullary , papillary , mucinous ( colloid ) , tubular histology Willing able provide consent Age &gt; =18 year . Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Appropriate stag study identify American Joint Committee Cancer ( AJCC ) stage 0 , I , II breast cancer . If stage II , tumor size must 3 cm less . Surgical treatment breast lumpectomy Clinical Target Volume ( CTV ) margin 5 cm maximum dimension histologically confirm margin free tumor ( negative margin define tumor ink direction ) . Reexcision surgical margin permit . Gross disease within breast must unifocal . ( Patients microscopic multifocality eligible long total extent tumor , gross microscopic , occupy volume great dimension 3 cm less ) Patients invasive disease require axillary stag include : sentinel node biopsy alone sentinel node negative , sentinel node biopsy follow axillary dissection minimum 6 axillary node sample sentinel node positive , axillary dissection alone ( minimum 6 axillary node ) . Patients DCIS require axillary staging . Patients history nonbreast invasive malignancy eligible diseasefree 3 year prior entry study T2 ( &gt; 3.0 cm ) , T3 , stage III , stage IV breast cancer More 3 histologically positive axillary lymph node axillary lymph node microscopic macroscopic extracapsular extension . Positive nonaxillary sentinel node evidence suspicious supraclavicular , infraclavicular , internal mammary node image physical exam , unless biopsied found negative tumor . Evidence physical examination mammography suspicious mass , density , microcalcifications either breast , unless biopsied found benign . Non epithelial breast malignancy sarcoma lymphoma . Multicentric gross breast carcinoma ( either DCIS invasive cancer ) microscopic breast carcinoma occupy volume maximum dimension 3 centimeter . Synchronous bilateral invasive noninvasive breast cancer . Paget 's disease nipple . Previous breast radiation ipsilateral side thoracic radiation ipsilateral side . Treatment plan include regional nodal irradiation . Any prior treatment radiation therapy chemotherapy currently diagnose breast cancer prior registration . Endocrine therapy may give within 28 day prior study entry must stop patient receive chemotherapy completion chemotherapy . Patients must discontinue hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators prior registration . Patients collagen vascular disease , specifically dermatomyositis Creatine phosphokinase ( CPK ) level normal active skin rash , systemic lupus erythematosis , scleroderma . Pregnancy lactation time registration . For woman childbearing age , must agree use effective contraceptive method condom/diaphragm spermicidal foam , intrauterine device , prescription birth control pill . Patients severe coextensive comorbidities significant psychiatric illness .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>